Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics Corporation has been awarded an Innovation Passport for their ChemoSeed product for high grade gliomas by the UK’s MHRA, expediting the treatment’s development and access. Additionally, the company has received a £25,000 grant from SPARK The Midlands to further support their innovative cancer treatment technology. The CEO, Andrew Webb, highlighted these recognitions as significant milestones and endorsements for the potential of ChemoSeed to transform brain tumour treatments.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
